Rare granulomatous processes
Authors:
J. Kufa 1; J. Novotná 1; M. Lukášová 2; V. Látal 2; V. Hanáčková 2; T. Tichý 3; D. Skanderová 3; N. Rušarová 4; P. Jakubec 1
Authors‘ workplace:
Klinika plicních nemocí a TBC LF UP a FN Olomouc
1; Hemato-onkologická klinika LF UP a FN Olomouc
2; Ústav klinické a molekulární patologie, LF UP a FN Olomouc
3; Onkologická klinika LF UP a FN Olomouc
4
Published in:
Transfuze Hematol. dnes,30, 2024, No. 2, p. 122-130.
Category:
Case Reports
doi:
https://doi.org/10.48095/cctahd2024prolekare.cz11
Overview
SUMMARY: The following three case reports describe patients who presented with respiratory symptoms and long-lasting B-symptoms. They were first considered to be suffering from infectious diseases. Sarcoidosis and other common conditions were excluded after a comprehensive examination. The patients were then diagnosed with idiopathic multicentric Castleman disease, lymphomatoid granulomatosis, and a granulomatous process of unknown aetiology coincident with chronic myelomonocytic leukaemia and later progression to acute leukaemia.
Keywords:
Castleman disease – granulomatous process – lymphomatoid granulomatosis
Sources
1. Cagle PT. Pulmonary pathology: an atlas and text, Third Edition, Philadelphia Wolters Kluwer, 2019: 251–277.
2. Cagle PT. Diagnostic pulmonary pathology, edit. Second Edition, Informa Healthcare USA, Inc., 2008: 285–317.
3. Adam Z, Řehák Z, Adamová Z, et al. Multicentrická Castlemanova choroba. Příznaky, diagnostika a léčba. Vnitř Lék. 2022; 68 (1): 41–53.
4. Adam Z, Řehák Z, Adamová Z, et al. Lokalizovaná (unicentrická) forma Castlemanovy nemoci. Klinické projevy, diagnostika a léčba dle mezinárodních doporučení z roku 2020. Vnitř Lék. 2021; 67 (8): 462–471.
5. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36 (7): 1720–1748.
6. Šimůnková M. Idiopatická multicentrická Castlemanova choroba: diagnostika a léčba v roce 2021. Acta Med. 2021; 12–13: 121–127.
7. Ostrowska B, Romejko-Jarosińska J, Domańska-Czyż K, Walewski J. Idiopathic multicentric Castleman disease: pathogenesis, clinical presentation and recommendations for treatment based on the Castleman Disease Collaborative Network (CDCN). Acta Haematol Pol. 2021; 52: 29–37.
8. van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020; 4: 6039–6050.
9. Král Z, Adam Z, Krejčí M, et al. Léčba multicentrické a unicentrické formy Castlemanovy nemoci, Transfuze Hematol Dnes. 2020; 26 (3): 186–195.
10. Adam Z, Volfová P, Ježová M, et al. Castlemanova nemoc, jedna z příčin chronické systémové zánětlivé reakce, někdy i retence tekutin, vaskulitid a poruch imunity – Mezinárodní diagnostická kritéria z roku 2017. Transfuze Hematol Dnes. 2020; 26 (2): 92–100.
11. Sýkorová A, Campr V, Kašparová P, et al. Lymfomatoidní granulomatóza – minulost a současnost. Vnitř Lék. 2014; 60 (3): 225–238.
12. Liebow AA, Carrington CRB, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol. 1972; (3): 457–558.
13. Balakrishnan P, Ing M, Househ Z, Raguparan A. Pulmonary lymphomatoid granulomatosis: An uncommon disease but not to be forgotten-a single centre experience. Respirol Case Rep. 2021; 9 (7): e00789
14. Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023; 482 (1): 227–244.
15. Pisani RJ, DeRemee RA. Clinical implications of the histopathologic diagnosis of pulmonary lymphomatoid granulomatosis. Mayo Clin Proc. 1990; 65 (2): 151–163.
16. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36 (7): 1703–1719.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2024 Issue 2
Most read in this issue
- VEXAS syndrome – newly described autoinflammatory disease with haematologic symptoms. Case report and review of the literature
- VEXAS syndrome – a diagnosis at the interface of rheumatology and haematology
- Disorders induced by deposits of monoclonal immunoglobulin IgM and free light chain in Waldenström’s macroglobulinaemia – case report and review of literature
- Splanchnic vein thrombosis: aetiology, therapy, and results – a retrospective analysis